Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma.
SiegelRLMillerKDFuchsHE, et al.
Cancer statistics. CA A Cancer J Clin2021;
71: 7–33.
2.
HowladerNNooneAMKrapchoM.SEER cancer statistics review, 1975-2016.
Bethesda, MD:
National Cancer Institute, 2019.
3.
KyleRAGertzMAWitzigTE, et al.
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;
78: 21–33.
4.
IslamiFGoding SauerAGapsturSM, et al.
Proportion of cancer cases attributable to excess body weight by US state, 2011-2015. JAMA Oncol2019;
5: 384–392.
5.
BummaNNagasakaMHemingwayG, et al.
Effect of exposure to agent orange on the risk of monoclonal gammopathy and subsequent transformation to multiple myeloma: a single-center experience from the veterans affairs hospital, Detroit. Clin Lymphoma Myeloma Leuk2020;
20: 305–311.
6.
SudAChattopadhyaySThomsenH, et al.
Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood2019;
134: 960–969.
7.
LandgrenOKristinssonSYGoldinLR, et al.
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood2009;
114: 791–795.
8.
RajkumarSV.Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol2020;
95: 548–567. [Erratum in: Am J Hematol 2020;95: 1444].
9.
AndersonKC. how far have we come? Mayo Clin Proc. 2003; 78(1): 15–17.
10.
RajkumarSVDimopoulosMAPalumboA, et al.
International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol2014;
15: e538-48–e548.
11.
VieraSLudekPZdeněkA, et al.
Monoclonal gammopathy of undetermined significance (MGUS) monoclonal gammopathy of undetermined significance (MGUS). Klin Onkol2018;
31: 270–276.
12.
KyleRADurieBGRajkumarSV, et al.; on behalf of the International Myeloma Working Group.
International myeloma working group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia2010;
24: 1121–1127.
13.
FurukawaYKikuchiJ.Molecular pathogenesis of multiple myeloma. Int J Clin Oncol2015;
20: 413–422.
14.
SonneveldPBroijlA.Treatment of relapsed and refractory multiple myeloma. Haematologica2016;
101: 396–406.
15.
RajkumarSVHarousseauJ-LDurieB, et al.; International Myeloma Workshop Consensus Panel 1.Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood2011;
117: 4691–4695.
CavoMRajkumarSVPalumboA, et al.; International Myeloma Working Group.
International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood2011;
117: 6063–6073.
18.
DurieBGMHoeringAAbidiMH, et al.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet2017;
389: 519–527.
19.
DurieBGMHoeringASextonR, et al.
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J2020;
10: 53.
20.
MoreauPPylypenkoHGrosickiS, et al.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol2011;
12: 431–440.
21.
KumarSFlinnIRichardsonPG, et al.
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood2012;
119: 4375–4382.
22.
ReederCBReeceDEKukretiV, et al.
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia2009;
23: 1337–1341.
23.
EinseleHLiebischPLangerC, et al.
Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (german DSMM XIa trial). Blood2009;
114: 131–131.
24.
FaconTKumarSPlesnerT, et al.
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med2019;
380: 2104–2115.
25.
BenboubkerLDimopoulosMADispenzieriA, et al.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med2014;
371: 906–917.
GrosickiSSimonovaMSpickaI, et al.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (boston): a randomised, open-label, phase 3 trial. Lancet2020;
396: 1563–1573.
29.
BahlisNJSutherlandHWhiteD, et al.
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood2018;
132: 2546–2554.
30.
VoglDTDingliDCornellRF, et al.
Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-cd38 ab refractory multiple myeloma (Mm): storm study. Blood2016;
128: 491–491.
31.
DeckertJWetzelM-CBartleLM, et al.
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res2014;
20: 4574–4583.
32.
MorenoLPerezCZabaletaA, et al.
The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res2019;
25: 3176–3187.
33.
MartinTStricklandSGlennM, et al.
A phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J2019;
9: 41.
34.
MikhaelJRichardsonPUsmaniSZ, et al.
A phase Ib study of isatuximab plus pomalidomide/dexatmethasone in relapsed/refractory multiple myeloma. Blood2019;
134: 123–133.
35.
AttalMRichardsonPGRajkumarSV, et al.
Isatuximab plus pomalidomide and low dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomized, multicenter, open-label, phase 3 study. Lancet2019;
394: 2096–2107.
36.
DimopoulosMALeleuXMoreauP, et al.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia2021;
35: 562–572.
37.
SchjesvoldFHRichardson Pg FaconT, et al.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021; 106(4): 1182–1187.
FinnGMaceSCampanaF, et al.
Evaluating isatuximab interference with monoclonal protein detection by immune-capture and liquid chromatography coupled to high resolution mass spectrometry in the pivotal phase 3 multiple myeloma trial, Icaria-MM. Blood2019;
134: 3143–3143.
42.
CaillonHIrimiaASimonJS, et al.
Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed DRIA test: Hydrashift 2/4 daratumumab. Blood2016;
128: 2063–2063.
43.
ChoSFAndersonKCTaiYT.Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-Based immunotherapy. Front Immunol2018;
9: 1821.
44.
TrudelSLendvaiNPopatR, et al.
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J2019;
9: 37.
45.
LonialSLeeHCBadrosA, et al.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol2020; 21(2): 207–221.
